Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow MRK
Merck & Co., Inc. (MRK) Return on equity
Merck & Co., Inc.'s return on equity over the twelve months to 30 June 2026 was 6.97%, down 29.9 percentage points from fiscal 2025 (36.9%). Over the past ten years it has ranged from 0.87% (fiscal 2023) to 41.0% (fiscal 2021); the current reading is higher than 73% of that period. That is above the Drug Manufacturers General industry median of 5.87% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 36.9% | (3.89) |
| FY2024 | 40.8% | 39.88 |
| FY2023 | 0.87% | (33.57) |
| FY2022 | 34.4% | (6.56) |
| FY2021 | 41.0% | 13.50 |
| FY2020 | 27.5% | (9.73) |
| FY2019 | 37.2% | 16.99 |
| FY2018 | 20.2% | 13.85 |
| FY2017 | 6.39% | (2.83) |
| FY2016 | 9.22% | (0.28) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 91.5% |
| NVO Novo Nordisk A/S compare | 60.8% |
| NVS Novartis AG compare | 30.4% |
| AZN AstraZeneca PLC compare | 22.0% |
| MRK Merck & Co., Inc. | 6.97% |
| PFE Pfizer Inc. compare | 4.97% |
| JNJ Johnson & Johnson compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −20.7% |
| ABBV AbbVie Inc. compare | −208.1% |
| Drug Manufacturers General industry median | 5.87% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement